Skip to main content

Table 2 Active Recruiting Current Clinical Trials with FAK Inhibitors in Various Malignancies

From: Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape

NCI Identifier Study Description Tumor Type Drug Combination with FAK inhibitor* Phase
NCT03287271 ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK Ovarian Paclitaxel, Carboplatin
VS-6063 (defactinib)*
I/II
NCT02758587 Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) NSCLC, Mesothelioma,
Pancreatic Neoplasms
Pembrolizumab
Defactinib*
I/II
NCT02523014 Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas Meningioma Vismodegib
GSK2256098*
II
NCT02546531 Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer Advanced solid tumors, Pancreatic Cancer Gemcitabine, Pembrolizumab
Defactinib
I
NCT02695550 Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer NSCLC CT-707* I
NCT03727880 Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma PDAC Pembrolizumab
Defactinib
II